Leucascandrolide A and neopeltolide are structurally homologous marine natural products that elicit potent antiproliferative profiles in mammalian cells and yeast. The scarcity of naturally available material has been a significant barrier to their biochemical and pharmacological evaluation. We developed practical synthetic access to this class of natural products that enabled the determination of their mechanism of action. We demonstrated effective cellular growth inhibition in yeast, which was substantially enhanced by substituting glucose with galactose or glycerol. These results, along with genetic analysis of determinants of drug sensitivity, suggested that leucascandrolide A and neopeltolide may inhibit mitochondrial ATP synthesis. Evaluation of the activity of the four mitochondrial electron transport chain complexes in yeast and mammalian cells revealed cytochrome bc 1 complex as the principal cellular target. This result provided the molecular basis for the potent antiproliferative activity of this class of marine macrolides, thus identifying them as new biochemical tools for investigation of eukaryotic energy metabolism.
Recent progress in bioassay-guided isolation and structure elucidation of natural products has placed increasing demands on the efficiency of modern organic synthesis, which is required to provide practical access to rare and biosynthetically inaccessible compounds in order to enable their biological and pharmacological evaluation en route to the ultimate development of new therapeutic agents 1 . In 1996, the search for new antiproliferative marine natural products resulted in the discovery of leucascandrolide A (1, Fig. 1 ), which was isolated from Leucascandra caveolata sponge and proved highly effective at suppressing growth of KB and P388 tumor cells, as well as the pathogenic yeast Candida albicans 2 . Isolation of neopeltolide (2, Fig. 1 ) from Daedalopelta sponge and a similarly potent antiproliferative profile of this marine macrolide were reported in 2007 (ref. 3) . Leucascandrolide A and neopeltolide share several notable structural features, including the trisubstituted tetrahydropyran subunit and an identical, highly unsaturated, oxazole-containing side chain, which suggests that the two natural products may inhibit cellular proliferation by a similar mechanism. The scarcity of the naturally available material, however, has been a significant barrier to establishing the mode of action of either natural product. Indeed, efforts to reisolate leucascandrolide A from its natural source have failed, perhaps reflecting that this polyketide-based natural product is produced by a bacterial symbiote rather than the sponge itself 2 . Thus, a significant synthetic effort has been made in developing chemical approaches for preparation of these complex natural products [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Initial efforts confirmed the proposed structure of leucascandrolide A (ref. 4) and revised the relative stereochemical assignment of neopeltolide 15, 16 , but the difficulty of preparing sufficient synthetic material has slowed discovery of molecular targets.
In this article, we describe elucidation of the mechanism of action of this class of marine natural products, which was enabled by practical chemical syntheses of a simplified congener of leucascandrolide A (3) and a recently revised structure of neopeltolide. Subsequent cell-based, genetics and biochemical studies of the two compounds in both mammalian cells and the brewers yeast Saccharomyces cerevisiae unambiguously established cytochrome bc 1 complex as the principal cellular target of this class of highly potent antiproliferative marine macrolides.
RESULTS
Synthesis of a simplified congener of leucascandrolide A Evaluation of the opposite enantiomers of leucascandrolide A (ref. 17) in a number of cancer cell lines and in S. cerevisiae revealed that the naturally occurring (+)-leucascandrolide A is only two-to three-fold more potent than the unnatural enantiomer ( Supplementary Fig. 1  online) . This observation, verified by additional structure-activity relationship studies 19 , indicated that the oxazole-containing side chain may be primarily responsible for the toxicity of leucascandrolide A and that the macrolide portion might be rationally simplified without affecting activity. Conformational analysis indicated that the axial C12 methyl group (Fig. 2) could be eliminated without affecting the conformation of the tricyclic macrolide subunit. Furthermore, the C17-C22 alkenyl moiety could be further simplified to a linear alkyl chain. However, removal of this alkyl group or inversion of the relative configuration at the C17 resulted in complete loss of biological activity 19 . This analysis suggested the revised target 3, in which the structural simplification offered substantial improvement of overall synthetic efficiency. Taking into account the similar activity of either enantiomer, synthesis of analog 3 was designed to deliver the final target in racemic form.
The synthesis of the engineered leucascandrolide A congener 3 is shown in Scheme 1. The approach followed our previously developed strategy 6, 17 beginning with the Paterson-Evans 1,5-anti selective aldol condensation 20, 21 of ketone 4 with aldehyde 5 and continuing with SmI 2 -mediated reduction, methylation and reductive removal of the acetate to give alcohol 6. Deprotection of the dioxolane and acetylation of the resulting lactol, followed by C-glycosidation, furnished aldehyde 7 with excellent overall efficiency and stereocontrol. Incorporation of the required alkyl fragment was achieved via the addition of n-pentyl magnesium bromide to aldehyde 7. Although both diastereomeric alcohols were obtained in equal amounts, the undesired diastereomer was readily separated by column chromatography and inverted via Mitsunobu reaction (not shown) to give the desired alcohol in 76% overall yield. Dihydroxylation, followed by Pb(OAc) 4 cleavage of the vicinal diol, afforded macrolactol 8 as a result of a spontaneous macrocyclization, which was originally observed during our synthesis of the parent natural product 6 . Subsequent oxidation, hydrogenolysis of the benzyl ether and final Mitsunobu esterification with oxazole-containing acid 10 (ref. 6) afforded the simplified congener of leucascandrolide A (3) with the longest linear sequence of 15 steps and a total of 24 steps. As expected, due to substantial simplification of the natural product's structure, the synthetic efficiency for the assembly of 3 compared favorably to our original synthesis of leucascandrolide A, which required a total of 34 steps with 18 steps in the longest linear sequence 6, 17 .
Synthesis of neopeltolide A using a common strategy The synthesis of neopeltolide is shown in Scheme 2. The assembly process began with the Prins desymmetrization 18 of diene 11, followed by benzyl protection and Wacker alkene oxidation to give ketone 12. Generation of boron enolate from ketone 12, followed by addition of aldehyde 13 (for preparation, see Supplementary Methods online), gave the expected aldol product with excellent diastereoselectivity (498:2) 20,21 , which was subjected to Wittig methylenation, followed by acidic removal of the dioxolane during the work-up to give ketone 14 in 75% yield for the two operations. 1,3-syn-selective reduction using Et 2 BOMe and NaBH 4 (ref. 22) , followed by saponification of ester with potassium trimethylsilanolate, gave the diol, which was subjected to the Yamaguchi macrolactonization to successfully assemble macrolide 15. As we expected, the macrocyclization proceeded with complete chemoselectivity to give the desired 14-membered macrolide in preference of the substantially more strained 12-membered lactone. Hydrogenation of alkene 15 using Pd/C catalyst proceeded with 3:1 diastereoselectivity to give the alcohol 16 as the major product isolated in 61% yield. Inversion of alcohol 16 was efficiently accomplished under the Mitsunobu conditions, followed by hydrolysis of the resulting p-nitrophenyl benzoate with K 2 CO 3 in MeOH. Subsequent methylation of the alcohol with MeO 3 BF 4 and hydrogenolysis of the benzyl ether afforded fully functionalized macrolide 17. The final step entailed coupling of the two fragments 10 (ref. 6 ) and 17, which was conducted under our standard Mitsunobu conditions 6 , to deliver neopeltolide with the longest linear sequence of 15 steps. The spectral data of this natural product were in excellent agreement with that described in the literature 3, 15, 16 .
Antiproliferative activity and cell cycle arrest We examined the effect of a simplified analog of leucascandrolide A (3) on proliferation of mammalian cells and the yeast S. cerevisiae. The dose-dependent suppression of growth of human tumor cell lines A549 (lung), PC3 (prostate) and HCT116 (colon) was established using a standard assay monitoring total cellular ATP (18) , and was further confirmed by counting cells in several representative experiments. Analog 3 elicited a highly potent antiproliferative profile and inhibited growth of cells by 50% at concentrations (GI 50 ) of 0.3-0.8 nM ( Supplementary Fig. 2a -c online), which is equal to that of the parent natural product 1. To evaluate the effect of leucascandrolide A on yeast cell growth, we performed disc-permeation assays using the W303-1A laboratory strain of S. cerevisiae as wild type. Analog 3 inhibited yeast growth in a zone with a diameter of 35 mm (11.2 mg of 3 per disc), comparable to the diameter of 33 mm inhibited by natural leucascandrolide A (11.2 mg of 1 per disc).
The synthetic neopeltolide inhibited cell growth with highly potent GI 50 values of 0.3-0.5 nM, in agreement with previously reported data 3 and with a pattern nearly identical to that observed with leucascandrolide A analog 3 ( Supplementary Fig. 2d-f ). For example, the HCT116 cell line proved to be the most sensitive to the two compounds, which inhibited the growth of these cells by 90% at 1.0 nM. In contrast, PC3 and A549 cell growth was inhibited by only 60% at the same concentration of 2 or 3.
Having established a highly potent cell-based antiproliferative profile of simplified leucascandrolide A congener 3, we evaluated the effect of this compound on cell cycle regulation. Exposure of HCT116 cells to analog 3 (100 nM) for 24 h resulted in a marked increase in the G0/G1 population to 61% from 45% in the control, and a decrease in the G2/M cell population to 6% from 12% ( Supplementary Fig. 3a online) . A similar G1 cell cycle delay was observed with the parent natural product 1 ( Supplementary Fig. 3b ).
Taking into account the reported G1 cell cycle arrest induced by neopeltolide 3 , the combination of similar cell-based activity profiles and the cell cycle inhibition by 2 and 3 strongly supports the hypothesis that the two natural product-based agents inhibit cell growth by the same mechanism. Whereas the W303-1A wild-type strain of S. cerevisiae displayed marked sensitivity to leucascandrolide analog 3 and neopeltolide 2 on agar medium containing 2% glucose (19) , almost no sensitivity to 3 was observed in the 2% glucose liquid medium YPD (Fig. 3a) . Replacing glucose with ethanol (20) or glycerol (21) slightly increased sensitivity to analog 3, whereas galactose (22) increased sensitivity to 3 over 10,000-fold (Fig. 3b) . In galactose medium, analog 3 induced a similar G1-shifted cell cycle profile in the budding yeast cells ( Supplementary Fig. 4 online) . Notably, adding glucose to the galactose-containing medium restored resistance to the drug and normal growth kinetics.
Genome-wide yeast deletion screen Previous work using yeast genetics to identify cellular targets of small molecules demonstrates the value of an organism with low complexity, powerful genetics and conserved cell cycle 23, 24 . We evaluated the activity of the leucascandrolide A analog in the library of 4,900 yeast strains comprising the yeast haploid non-essential gene deletion collection. The screen was aimed at providing additional information about the mechanism of action en route to the ultimate discovery of the cellular target. We examined the effect of analog 3 on growth inhibition of each member of the yeast haploid deletion library grown in a 96-well format, aiming to identify the supersensitive organisms. Growth inhibition of each mutant strain cultured in liquid medium containing 2% galactose was measured by monitoring the optical density at 600 nm at 24 h intervals in the presence of three concentrations of analog 3 (0 nM, 5 nM and 25 nM). Quantitative analysis of growth rates revealed several supersensitive deletion mutants, which were subdivided into three categories: (i) genes involved in pathways for drug inactivation via transport and/or secretion of metabolites (ATG11, ERG3, ERG6, KCS1, PPA1, RVS161 and VMA8), (ii) key regulators of glucose metabolism (SNF4, SNF5 and SNF6) and (iii) genes involved in amino acid biosynthesis (HOM3, SER1 and SER2). Among these mutants, the strain carrying a deletion of the SNF4 gene also demonstrated slow growth on galactose alone ( Supplementary Fig. 5a online), but was particularly sensitive to leucascandrolide A analog 3 ( Supplementary Fig. 5b ). SNF4 encodes a regulatory subunit of the yeast homolog of the heterotrimeric AMP-activated protein kinase AMPK. Mammalian AMPK is stress responsive, in part via sensing the cellular AMP:ATP ratio, and is thus activated by metabolic stresses that inhibit ATP production or stimulate consumption. Similarly, Snf4 along and its binding partner, the protein serine/threonine kinase Snf1, are required for adaptation to growth on low glucose, unfavorable sugars such as galactose and nonfermentable carbon sources such as glycerol and ethanol 25, 26 . Though galactose is fermentable, yeast grown semi-anaerobically on galactose medium demonstrate increased respiration and elevated mitochondrial cytochromes 27 . The pattern of sensitivity to nonglucose carbon sources and the marked supersensitivity of the snf4 knockout strain raised the possibility that leucascandrolide A may antagonize a pathway required for ATP biosynthesis in the absence of glucose fermentation, such as mitochondrial oxidative phosphorylation.
Inhibition of oxidative phosphorylation
To further probe this hypothesis, we used a disc diffusion assay to examine yeast sensitivity to analog 3 when glucose was replaced with the nonfermentable carbon source glycerol (Fig. 4a,b) . Glycerol metabolism requires a shift in ATP production to oxidative phosphorylation, and cells lacking mitochondrial respiration (petites) are unable to grow on glycerol alone. Increased sensitivity to analog 3 in glycerol-containing medium was evident both in the larger diameter and in the complete lack of cell growth within the zone of inhibition. We next examined the effect of analog 3 on the growth of r 0 petite yeast. Because they lack mitochondrial DNA and thus genes encoding key components of the electron transport chain, r 0 cells are incapable of producing ATP by oxidative phosphorylation and can grow only via glycolysis. Consistent with both drugs targeting oxidative phosphorylation, neither leucascandrolide A analog 3 nor neopeltolide further inhibited growth of r 0 petite yeast compared to their effects on the r + control (Fig. 4c,d ). As expected, cycloheximide (23) inhibited growth of r 0 petite yeast.
Because higher eukaryotes use similar pathways for cellular ATP production, we next tested the effects of leucascandrolide A analog 3 and neopeltolide on modulation of oxidative phosphorylation in mammalian cells. Our strategy was to use 2-deoxyglucose (24, 2-DG) to block glycolysis 28 and thereby reveal the effects of 2 and 3 on ATP production by oxidative phosphorylation. Treatment of A549 cells with either 2 or 3 for 30 min in the presence of 2-DG decreased ATP concentration with half-maximal inhibitory concentrations (IC 50 s) of 1.3 and 2.6 nM, respectively (Fig. 5a,b) . As predicted, ATP levels were not affected by the spindle toxin paclitaxel (25) in the presence of 2-DG (Fig. 5c) . The effect appeared specific to oxidative phosphorylation as the level of ATP remained relatively constant during the first 30 min after incubation of cells with either 2 or 3 in the absence of 2-DG (Fig. 5d,e) .
To confirm these results, we examined the effect of analog 3 on cellular respiration by monitoring oxygen consumption in 143B cells. Oligomycin A (26) , an inhibitor of the mitochondrial Fo/F1 ATP synthase 29 , decreased oxygen uptake, and treatment of these cells with carbonyl cyanide m-chlorophenyl hydrazone (27, CCCP) 30 to uncouple mitochondrial respiration from ATP synthesis restored respiration (Fig. 6a) . As expected, treatment of cells with NaCN, which inhibits complex IV of the electron transport chain, blocked respiration irreversibly. Treatment of 143B cells with leucascandrolide A analog 3 inhibited respiration in a dose-dependent fashion. Unlike the oligomycin control, the respiration of the treated cells was not restored by CCCP, which indicated that analog 3 did not influence the activity of ATP synthase (Fig. 6b) . Treatment of HCT116 cells with 3 resulted in a 40% increase in NADH (28) fluorescence of cells at 457 nm (Fig. 6c) , which is an indicator of inhibition of electron transport in mitochondria. Rotenone (29) , which inhibits complex I, was used as a positive control in these studies. In addition, treatment of isolated, sonicated yeast mitochondria with leucascandrolide A analog 3 (10 nM) or neopeltolide (10 nM) resulted in complete inhibition of NADH oxidation compared to DMSO control ( Supplementary  Fig. 6a online) . Given that NADH oxidation is dependent on the activity of complexes I, III and IV, our data indicate that leucascandrolide A and neopeltolide may elicit their potent antiproliferative activity by blocking one or more complexes in the mitochondrial electron transport chain.
Inhibition of cytochrome bc 1 complex
To identify a specific electron transport complex that is inhibited by leucascandrolide A and neopeltolide, we measured the enzymatic activity of each protein complex involved in oxidative phosphorylation in sonicated yeast mitochondria. We found that treatment of isolated mitochondria with either 3 or 2 resulted in highly potent dose-dependent inhibition of the activity of complex III (also referred to as cytochrome bc 1 complex or ubiquinol:cytochrome c oxidoreductase) with IC 50 s of 1.8 and 0.6 nM, respectively ( Supplementary  Fig. 6b,c) . None of the other respiratory chain complexes were affected by the two natural products ( Supplementary Fig. 7 online) .
To test the effect of leucascandrolide A analog (3) and neopeltolide on the activity of purified bovine heart mitochondrial cytochrome bc 1 complex, we monitored reduction of cytochrome c by the purified enzyme. Analog 3 inhibited the activity of this protein complex by 50% at a concentration of 6.0 nM (Fig. 6d) . Neopeltolide displayed a similar activity profile (IC 50 2.0 nM, Fig. 6d ).
To gain additional insight into the mechanism of inhibition of cytochrome bc 1 complex, we carried out a series of spectroscopic studies that enable monitoring of changes in the oxidation states of cytochromes. Treatment of sonicated yeast mitochondria with leucascandrolide-based analog 3 resulted in levels of reduced cytochrome b similar to that observed using typical P-type inhibitors (Supplementary Fig. 8 online) .
DISCUSSION
The mitochondrial electron transport chain consists of four major components, which are designated as complexes I, II, III and IV (ref. 31) . Ubiquinone (coenzyme Q10) and cytochrome c are responsible for the communication between the four transmembrane complexes enabling the electron flow through the chain from NADH dehydrogenase (complex I) to cytochrome c oxidase (complex IV) 31 . Cytochrome bc 1 (complex III) is a transmembrane protein 90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20 10 complex located in the inner mitochondrial membrane [32] [33] [34] . This multi-subunit enzyme is a central component of the mitochondrial respiratory electron transport chain 35 . The function of cytochrome bc 1 is to reduce cytochrome c(Fe 3+ ) into cytochrome c(Fe 2+ ) using the membrane-localized ubiquinol. The free energy of the proton-coupled electron transfer reaction, which is often referred as the protonmotive Q cycle 36, 37 , contributes to the proton gradient across the mitochondrial membrane to enable subsequent ATP production by ATP synthase.
Our work demonstrates that practical chemical synthesis of leucascandrolide A and neopeltolide, in the absence of any other means of accessing such compounds, enables comprehensive genetic and biochemical investigation of the molecular mechanism of action. This effort resulted in identification of cytochrome bc 1 complex as the cellular target of the two marine natural products. Highly potent cellbased antiproliferative activity of leucascandrolide A and neopeltolide compares favorably to that of the most potent inhibitors of cytochrome bc 1 complex known today, thus identifying such compounds as a new class of highly useful biochemical tools for investigation of eukaryotic energy metabolism.
It is noteworthy that leucascandrolide A and neopeltolide do not share any significant degree of structural homology with previously reported small-molecule inhibitors of cytochrome bc 1 complex, including P-type inhibitors (myxothiazol (30) and stigmatellin (31)) [38] [39] [40] , ubiquinone mimetics 41 and N-type inhibitors (antimycin A (32)) 42, 43 . Our studies demonstrate that leucascandrolide-based analog 3 and neopeltolide are exceedingly potent at inhibiting the activity of cytochrome bc 1 complex. Such potent inhibition of isolated cytochrome bc 1 complex by 2 and 3 was fully consistent with the ability of the two compounds to inhibit cell growth, ATP production, respiration and complex III activity in yeast mitochondria at similarly low concentrations. Our preliminary investigation revealed that the effect of compound 3 on reduction of cytochrome b in yeast mitochondria appears to be similar to that observed for P-type inhibitors of complex III, such as myxothiazol and stigmatellin. The detailed biophysical and biochemical investigation of the mechanism of inhibition of cytochrome bc 1 complex by leucascandrolide A and neopeltolide is currently in progress.
Oxidative phosphorylation and glycolysis are tightly coupled in eukaryotic cells. Due to the increased dependency of tumor cells on glycolysis, known as the Warburg effect 44 , and its likely role in promoting cell proliferation, survival and invasion 45 , disruption of energy metabolism in cancer cells is of significant current interest for the development of a new class of anticancer agents 46 . Several recent studies have demonstrated that the induction of hypoxia-like conditions using inhibitors of oxidative phosphorylation hypersensitizes tumor cells to treatment with glycolytic inhibitors 47, 48 . Thus, a combination of suppressors of oxidative phosphorylation with inhibitors of glycolysis could represent a strategy for metabolic sensitization of tumor cells to cytotoxic and targeted therapies.
METHODS
General. Dichloromethane (HPLC grade), ethyl acetate (American Chemical Society (ACS) grade), hexanes (ACS grade) and diethyl ether (ACS grade) were purchased from Fisher Scientific and used without further purification. Anhydrous tetrahydrofuran was purified by distillation from sodium benzophenone. Commercially available reagents were used without further purification. Reactions were monitored by TLC using Whatman precoated glass silica gel plates. Flash column chromatography was performed over Silacycle silica gel (230-400 mesh). 1 H NMR and 13 C NMR spectra were recorded on Bruker DRX-400 or DMX-500 spectrometers using residual solvent peaks as an internal standard. Mass spectra were recorded with a VG Instruments model 7070EQ tandem mass spectrometer. All cell lines, media, sera and supplements were purchased from the American Type Culture Collection (ATCC). CellTiterGlo luminescent cell viability assay was purchased from Promega. SensoLyte culture dishes, 96-well plates and all other supplies were purchased from Fisher Scientific. Luminescence was measured on a Perkin-Elmer Victor 3 plate reader. Oligomycin A (26), 2-deoxy-D-glucose (24) , paclitaxel (25) , CCCP (27) , rotenone (29) , cyclohexamide (23) and cytochrome c from equine heart were purchased from Sigma-Aldrich.
Cell lines and culture. A549, PC3 and HCT116 cell lines were purchased from ATCC. A549 and PC3 cells were maintained in F12-K medium; HCT116 cells were maintained in McCoy's 5A modified medium. Media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin-glutamine solution. 143B cell line was maintained in minimum essential medium (MEM) supplemented with 10% FBS, 1% penicillin-streptomycin solution, 0.1% BrdU and 2% sodium pyruvate.
Yeast strain and media. The S. cerevisiae strain was W303-1A (MATa ade2-1 can1-100 ura3-1 leu2-3, 112 his3-11, 15 trp1-1). Yeast cells were grown in standard rich YPD (1% yeast extract, 2% peptone, 2% glucose), YPGal (1% yeast extract, 2% peptone, 2% galactose) and YPGly (1% yeast extract, 2% peptone, 3% v/v glycerol) media. Petite mutants of W303-1A strain were obtained by treatment with 25 mg of ethidium bromide per ml in 0.67% Difco yeast nitrogen base with 2% glucose and relevant nucleotides and amino acids for W303-1A. After culture was grown to saturation, a small inoculum was transferred to ethidium bromide-free medium, and cells were grown to saturation and streaked on YPD. r 0 petite colonies were identified by colony color (W303-1A wild-type colonies are red on YPD medium, petite mutants are white) and by assessing their lack of growth on YPGly agar plates.
Disc permeation assay. Yeast was grown to saturation in YPD medium at room temperature (18 1C). Cultures were diluted by a factor of 10, and 0.25 ml of cell suspension was spread onto YPD or YPGly plates. Small molecules and DMSO were dissolved in 20 ml of water and added to the paper discs, which were placed on top of agar. Plates were incubated for 2-3 d at 30 1C.
Yeast growth inhibition assay in liquid media. All assays were performed using two replicate wells for each compound concentration test. Yeast suspension in logarithmic phase was distributed in a 96-well plate. Cells were treated with graded concentrations of the small molecule, and growth rates were measured by determination of the optical density at 600 nm (OD 600 ) as a function of time using a PowerWave microplate spectrophotometer (BioTek).
ATP measurement. All assays were performed using two replicate wells for each small-molecule concentration test. A549 cells were seeded in 96-well plates at a density of 2,500 cells well -1 and incubated for 4 h. Cells were then treated with graded concentrations of small molecules and incubated for 30 min. CellTiterGlow kit (Promega) was used to measure ATP levels. Luminescence was quantified as described before. Whole-cell ATP content (nmol cell -1 ) was determined using an ATP standard curve.
Measurement of cellular respiration. Cellular O 2 consumption rates were measured in aliquots of 143 B cells (4 Â 10 6 cells) in serum-free medium and studied in a magnetically stirred, water-jacked (37 1C) respirometer chamber using an oxygen electrode (Hansatech Instruments). Oxygraph Plus software (Hansatech) was used to determine oxygen consumption rate.
Measurement of cellular NADH level. Changes in cellular NADH concentrations were assessed from changes in the autofluorescence of cells by confocal microscopy at an excitation wavelength of 350 ± 25 nm and an emission wavelength of 457 ± 25 nm. Autofluorescence was measured using a DSU spinning disk confocal microscope (Olympus). HCT116 cells were seeded to collagen-coated dishes (MatTek) at a density of 200,000 cells dish -1 . Cells were allowed to proliferate for 41 h at 37 1C. Fresh medium was added, and cells were incubated for 30-60 min. Samples were placed into a dish holder maintained at 37 1C, and fluorescence was measured every 30 s. As soon as initial autofluorescence was obtained, small molecules were added and measurements were done for an additional 4 min. Percent change in NADH
